Quarterly report pursuant to Section 13 or 15(d)

SEGMENT REPORTING (Tables)

v3.21.1
SEGMENT REPORTING (Tables)
3 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]

Information concerning the operations of the Company’s reportable segments is as follows:

 

   

BioSig

Technologies, Inc.

   

ViralClear

Pharmaceuticals, Inc.

   

NeuroClear

Technologies,

Inc.

   

Total

 

Revenue:

                               

Product sales

  $ 115,367     $ -     $ -     $ 115,367  

Service

    2,680       -       -       2,680  

Total Revenue

    118,047       -       -       118,047  
                                 

Cost of goods sold

    98,618       -       -       98,618  
                                 

Gross profit

    19,429       -       -       19,429  
                                 

Operating expenses:

                               

Research and development

    1,275,993       (10,286

)

    -       1,265,707  

General and administrative

    6,456,625       814,386       450       7,271,461  

Depreciation and amortization

    40,728       857       -       41,585  

Total operating expenses

    7,773,346       804,957       450       8,578,753  
                                 

Loss from operations

    (7,753,917

)

    (804,957

)

    (450

)

    (8,559,324

)

                                 

Other income:

                               

Interest income and other income, net

    606       114       -       720  
                                 

Net loss

  $ (7,753,311

)

  $ (804,843

)

  $ (450

)

  $ (8,558,604

)

 

   

BioSig

Technologies, Inc.

   

ViralClear

Pharmaceuticals, Inc.

   

NeuroClear

Technologies,

Inc.

   

Total

 

Operating expenses:

                               

Research and development

  $ 1,327,003     $ 3,599,711     $ -     $ 4,926,714  

General and administrative

    3,819,438       4,035,782       -       7,855,220  

Depreciation and amortization

    21,015       -       -       21,015  

Total operating expenses

    5,167,456       7,635,493       -       12,802,949  
                                 

Loss from operations

    (5,167,456

)

    (7,635,493

)

    -       (12,802,949

)

                                 

Other income:

                               

Interest income and other income, net

    25,411       14,165       -       39,576  
                                 

Net loss

  $ (5,142,045

)

  $ (7,621,328

)

  $ -     $ (12,763,373

)

 

   

BioSig

Technologies, Inc.

   

ViralClear

Pharmaceuticals, Inc.

   

NeuroClear

Technologies,

Inc.

   

Total

 

Cash

  $ 18,060,472     $ 4,414,394     $ -     $ 22,474,866  

Inventory

    649,937       -       -       649,937  

Other current assets

    203,757       4,989       -       208,746  

Total operating assets

    18,914,166       4,419,383       -       23,333,549  
                                 

Property and equipment, net

    373,684       7,717       -       381,401  

Right-to-use assets, net 

    356,266       -       -       356,266  

Other assets

    444,743       -       -       444,743  
                                 

Total assets

  $ 20,088,859     $ 4,427,100     $ -     $ 24,515,959